Therapeutics and Diagnostics for Women's Disorders

Therapeutics and Diagnostics for Women's Disorders

This Report:

• Covers a wide variety of products and disorders that predominantly affect women including autoimmune diseases, women’s cancer, gynecological infections and diseases, reproductive-related therapies and diagnostics, rheumatoid arthritis and osteoporosis
  
  
• Includes U.S. market forecasts for therapeutics and diagnostics for women’s disorders through 2014
  
  
• Provides detailed information based on product categories and their use
  
  
• Discusses new therapeutics and diagnostics that have emerged and have a significant impact on women’s health
  
  
• Profiles leading companies.

CHAPTER ONE: INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

SCOPE OF REPORT

METHODOLOGY

RELATED BCC STUDIES

ANALYSTS CREDENTIALS

BCC RESEARCH ONLINE SERVICES

DISCLAIMER

CHAPTER TWO: SUMMARY

SUMMARY TABLE U.S. MARKET FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, THROUGH 2013 ($ MILLIONS)

SUMMARY FIGURE U.S. MARKET FORECAST FOR NEW THERAPEUTICS AND DIAGNOSTICS FOR WOMEN’S DISORDERS BY SEGMENT, 2006-2013 ($ MILLIONS)

CHAPTER THREE: INDUSTRY OVERVIEW

DEFINITION OF WOMEN’S DISORDERS

IMPORTANCE OF THE INDUSTRY AND DEMOGRAPHICS

TABLE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)

FIGURE 1 ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2000-2020 (YEARS)

TABLE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

FIGURE 2 PROJECTED GLOBAL FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

TABLE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, THROUGH 2030 (MILLIONS)

FIGURE 3 PROJECTED UNITED STATES FEMALE POPULATION BY AGE, 2000-2030 (MILLIONS)

HISTORY OF THE INDUSTRY AND RESPONSE TO WOMEN’S HEALTHCARE NEEDS

REGULATORY ENVIRONMENT

EFFECTS OF AGING

FIGURE 4 FEMALE LIKELIHOOD OF GETTING PREGNANT VERSUS INFERTILITY AS AGE PROGRESSES, 2008 (%)

CONTRACEPTIVE INSURANCE COVERAGE

TABLE 4 INSURANCE COVERAGE OF CONTRACEPTIVES BY STATE

CONTRACEPTIVE USE IN TEENS INCREASES

NEW USE FOR CONTRACEPTIVES

AGING AND INFERTILITY

CONTRACEPTIVE PATCH LINKED TO DEATHS

WOMEN AND SEXUAL HEALTH

INCIDENCE OF SEXUAL DYSFUNCTION

VASCULAR TREATMENTS AND SEXUAL DYSFUNCTION

DIAGNOSTICS

NEW DEVELOPMENTS IN SEXUAL DYSFUNCTION TREATMENTS FOR WOMEN

Alista

TABLE 5 U.S. SEXUAL DYSFUNCTION PRODUCTS FOR WOMEN IN DEVELOPMENT, 2008

SEXUAL DYSFUNCTION IN CANCER

INFERTILITY AND CANCER

CHEMOTHERAPY

RADIATION

PREVENTION STRATEGIES

MARKETING AND WOMEN

COUNTERFEIT PHARMACEUTICALS

GENERIC PARTICIPATION

TABLE 6 U.S. PRESCRIPTION GENERIC DRUG APPROVALS FOR CONSTRACEPTION BY COMPANY AND APPROVAL DATE, 2003-2008

INTERNATIONAL ISSUES

CHAPTER FOUR: AUTOIMMUNE DISEASES

U.S. MARKET OVERVIEW

MARKET SIZE

TABLE 7 U.S. MARKET FORECAST FOR AUTOIMMUNE DISEASES BY PRODUCT SEGMENT, THROUGH 2013 ($ MILLIONS)

COMPETITIVE ANALYSIS

TABLE 8 MANUFACTURERS OF AUTOIMMUNE DISEASE PRODUCTS, 2008

TABLE 9 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 ($ MILLIONS)

FIGURE 5 U.S. SUMMARY OF AUTOIMMUNE DISEASE MARKET BY COMPETITOR REVENUES, 2008 (%)

MARKET BY DISEASE TYPE

CHRONIC FATIGUE SYNDROME

Incidence and Mortality

Market Indicators

FIBROMYALGIA

Incidence

Diagnostics

Pain in 11 of 18 Tender Point Sites on Digital Palpation

Market Indicators

Current Market Participants

MYASTHENIA GRAVIS

Incidence and Mortality

Diagnostics

Market Indicators

Current Market Participants

SJOGREN’S SYNDROME

Incidence and Mortality

Diagnostics

<